adalimumab-fkjp — CareFirst (Caremark)

Initial criteria

• Adult member with active psoriatic arthritis
• If previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for PsA, approval may be granted

Reauthorization criteria

• Chart notes or medical record documentation supporting positive clinical response

Approval duration

12 months